Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 17.82 USD 4.58% Market Closed
Market Cap: 13.3B USD

Summit Therapeutics Inc
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Summit Therapeutics Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Summit Therapeutics Inc
NASDAQ:SMMT
Operating Expenses
-$211m
CAGR 3-Years
-34%
CAGR 5-Years
-50%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$22.7B
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$5.6B
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$8.4B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
No Stocks Found

Summit Therapeutics Inc
Glance View

Summit Therapeutics Inc., headquartered in Cambridge, Massachusetts, has carved a niche in the biopharmaceutical landscape with its focus on addressing serious unmet medical needs, primarily through the development of innovative antibiotics and therapies. The company gained significant attention with its efforts to combat antibiotic resistance, a global health threat. Their flagship endeavor, Ridinilazole, is an antibiotic designed to treat C. difficile infections, a prevalent and often severe bacterial infection affecting the gut. The company's proposition is simple yet impactful: develop effective treatments that not only address infections but also potentially reduce recurrence, thereby offering a better therapeutic alternative to existing solutions. Summit's business model is built around advancing their drug pipeline through rigorous clinical trials, securing regulatory approvals, and ultimately achieving commercialization either independently or through strategic partnerships. The partnerships are critical, as they allow Summit to leverage the expertise and market reach of larger pharmaceutical companies. Additionally, these alliances provide financial backing, helping offset the costly nature of drug development. Revenue is primarily driven from these collaborations through milestone payments and eventual product royalties, once their therapies hit the market. This strategic approach allows Summit to focus its resources on research and development while aligning with partners to navigate the complexities of bringing new therapies to patients globally.

SMMT Intrinsic Value
Not Available

See Also

What is Summit Therapeutics Inc's Operating Expenses?
Operating Expenses
-211m USD

Based on the financial report for Dec 31, 2024, Summit Therapeutics Inc's Operating Expenses amounts to -211m USD.

What is Summit Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-50%

Over the last year, the Operating Expenses growth was -138%. The average annual Operating Expenses growth rates for Summit Therapeutics Inc have been -34% over the past three years , -50% over the past five years .

Back to Top